Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 4/20 | 0.37 |
| ▸ | THRA | P10827 | 1/20 | 0.34 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.33 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18431534 | 0.93 | TSHR (0.39) | TSHRHPGDTHRBTHRAZDHHC20 | |
| SCHEMBL18743380 | 0.89 | TSHR (0.41) | TSHRHPGDTHRBTHRAALDH1A1 | |
| SCHEMBL19069273 | 0.86 | TSHR (0.41) | TSHRHPGDTHRBTHRAZDHHC20 | |
| SCHEMBL24690713 | 0.81 | TSHR (0.42) | TSHRHPGDTHRBTHRAZDHHC20 | |
| SCHEMBL18737306 | 0.80 | TSHR (0.41) | TSHRHPGDTHRBTHRAZDHHC20 | |
| SCHEMBL20927046 | 0.80 | TSHR (0.41) | TSHRHPGDTHRBTHRAZDHHC20 | |
| SCHEMBL18469790 | 0.79 | TSHR (0.40) | TSHRHPGDTHRBTHRAZDHHC20 | |
| SCHEMBL18897091 | 0.79 | TSHR (0.38) | TSHRHPGDTHRBLMNAALDH1A1 | |
| SCHEMBL5455576 | 0.76 | TSHR (0.43) | TSHRHPGDTHRBTHRAZDHHC20 | |
| SCHEMBL227180 | 0.75 | TSHR (0.42) | TSHRHPGDTHRBTHRAZDHHC20 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242548-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242548-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | TSHR 4752/4885HPGD 1795/4885THRB 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.